ArticleMicrobial biotechnology2025
Improvement of β-Xylosidase and Endoxylanase Activities in Talaromyces amestolkiae by Genetic Manipulation of the Transcriptional Activator XlnR.
Article in Microbial biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Phylogenetic analysis of xylan-degrading hemicellulases fromFrontiers in microbiology · 2026Article
- Beyond Sugar: A Holistic Review of Sweeteners and Their Role in Modern Nutrition.Foods (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The ascomycete Talaromyces amestolkiae is a promising source of glycosyl hydrolases for hemicellulose degradation, as it contains a considerably higher number of genes encoding these enzymes than other fungi exploited for plant biomass valorisation. The development of genetic engineering tools could further improve its biotechnological potential. We report here a transformation system for T. amestolkiae based on pyrimidine auxotrophy complementation, which was used to successfully introduce both integrative and autonomously replicating plasmids. Then, we applied this tool to force the expression of the transcriptional activator XlnR, generating an engineered strain with enhanced β-xylosidase (1.4-fold) and endoxylanase (2.0-fold) activities compared to the wild-type cultured on xylan. Markedly larger improvements were obtained after introducing Ala788Val or Val785Phe substitutions in XlnR, achieving 3.3-fold and 3.9-fold increases in β-xylosidase and endoxylanase activities, respectively, in the case of XlnR
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.